NIHR Signal: GLP-1 drug for diabetes gives modest cardiovascular benefits compared with placebo

Expert commentary is provided for a meta-analysis which found an NNT of 75 over 3.2 years for preventing one serious cardiovascular event for GLP-1 agonists vs placebo. There was no statistical heterogeneity between the trials, which showed a 12% reduction in this endpoint.


NIHR Dissemination Centre